Clinical Trials · NCT00769795
Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- University of Washington
- Enrollment
- 29
- Start date
- Oct 2008
- Locations
- 3 sites, United States
- Primary endpoint
- The primary endpoint of the study is to determine the effects of combining androgen deprivation with IMC-A12 on pathologic tumor stage (pathologic complete response).